Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
4.500
+0.040 (0.90%)
At close: Jan 21, 2025, 4:00 PM
4.590
+0.090 (2.00%)
After-hours: Jan 21, 2025, 5:01 PM EST
Aptevo Therapeutics Employees
Aptevo Therapeutics had 40 employees as of December 31, 2023. The number of employees decreased by 5 or -11.11% compared to the previous year.
Employees
40
Change (1Y)
-5
Growth (1Y)
-11.11%
Revenue / Employee
n/a
Profits / Employee
-$593,025
Market Cap
2.25M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
APVO News
- 6 days ago - Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025 - Accesswire
- 5 weeks ago - Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds - Accesswire
- 5 weeks ago - 100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial - Accesswire
- 6 weeks ago - Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects - Accesswire
- 7 weeks ago - Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan - Accesswire
- 2 months ago - Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation - Accesswire
- 2 months ago - Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm - Accesswire
- 2 months ago - First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies - Accesswire